β-elemene blocks lipid-induced inflammatory pathways via PPARβ activation in heart failure

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Heart failure (HF) is a complex syndrome characterized by impaired cardiac function and often involves lipid metabolism dysfunction and inflammation.
• Beta-elemene, a natural compound, has shown potential therapeutic properties, but its effects on heart failure and underlying mechanisms require further investigation.

Purpose of the Study:

• To investigate the therapeutic effects of beta-elemene on a mouse model of heart failure (HF).
• To elucidate the in vitro mechanisms by which beta-elemene exerts its protective effects against cardiac dysfunction, focusing on lipid metabolism and inflammation.

Main Methods:

• Established left anterior descending (LAD)-induced HF mouse models and oxygen-glucose deprivation/recovery (OGD/R)-induced H9C2 cell models.
• Utilized histological examination, Western blot, quantitative real-time PCR (RT-qPCR), immunofluorescence staining, and molecular docking.
• Assessed cardiac function parameters (ejection fraction, fractional shortening) and inflammatory markers (NF-κB, IL-6, TNFα).

Main Results:

• Beta-elemene improved cardiac function in HF mice, increasing ejection fraction and fractional shortening.
• Administration of beta-elemene reduced ventricular dilation, lipid accumulation, and inflammatory infiltration in myocardial infarction areas.
• In vitro studies showed beta-elemene enhanced fatty acid oxidation gene expression (PPARβ) and increased CPT1A and SIRT3 levels, while suppressing inflammatory pathways (NF-κB, IL-6, TNFα).

Conclusions:

• Beta-elemene demonstrates significant therapeutic potential for heart failure by improving cardiac function and reducing lipid accumulation and inflammation.
• The mechanism involves the upregulation of fatty acid oxidation pathways, particularly involving PPARβ, and the suppression of pro-inflammatory signaling.
• These findings support beta-elemene as a promising candidate for novel heart failure therapies.